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The short stature homeobox gene ( SHOX ; NM_00451) encodes a homeodomain transcription factor involved in the regulation of chondrocyte differentiation and proliferation; it plays an important role in human skeletal growth, being specifically expressed in the growth plate [Marchini et al., 2007; Binder, 2011] . SHOX is located in the pseudoautosomal region 1 (PAR1) of the human sex chromosomes (Xp22.3 and Yp11.3). PAR1 genes do not undergo X inactivation and 2 copies of the SHOX gene are expressed, one from each of the sex chromosomes [Marchini et al., 2007; Iughetti et al., 2009; Binder, 2011] .
Subjects with monoallelic mutations or deletions within the SHOX coding or enhancer regions have variable degrees of growth impairment, with or without the spectrum of skeletal anomalies consistent with the mesomelic skeletal dysplasia known as Léri-Weill dyschondrosteosis (LWD) [Iughetti et al., 2009; Binder, 2011] . SHOX haploinsufficiency has been found in 60-90% of patients with LWD and in 5-17% of children diagnosed as idiopathic short stature [Huber et al., 2006; Rappold et al., 2007; Rosilio et al., 2012; Wolters et al., 2013] . Patients with extra copies of SHOX due to sex chromosome trisomies are usually characterized by tall stature [Aksglaede et al., 2008] , supporting the dosage-dependent action of SHOX on growth [Marchini et al., 2007; Iughetti et al., 2009; Binder, 2011] .
Whereas patients with triple sex chromosome constitution are relatively common, complete or partial duplications limited to PAR1 including SHOX are extremely rare. Duplications of SHOX have been described in individuals with short, normal or tall stature [Roos et al, 2009; Thomas et al, 2009; D'haene et al., 2010; Benito-Sanz et al., 2011] , leading to some uncertainty on the effect of SHOX duplication on growth.
Here, a boy with impaired growth and 3 copies of SHOX , due to a Y-chromosome rearrangement is described.
Clinical Report
The boy of Brazilian origin was born after an uncomplicated pregnancy and adopted by Italian parents when he was 3 years old. Normal birth weight was affirmed in his clinical record, but raw values and auxological data from his parents were not available.
Auxological data at adoption are summarized in table 1 showing impaired linear growth and body weight. The boy came to our attention on account of short stature at the age of 9.5 years. His weight and body mass index (BMI) were normal, but he did not reach adequate height for his age ( table 1 ). He had mild cubitus valgus and a short neck, but Madelung deformity was not present. The sitting height/standing height ratio was at the 97th percentile ( table 1 ), suggesting body disproportion because of abnormal leg length. Bone age was 9.0 years (-0.96 SD), carpal and epiphyseal angles were 135° (n.v. <120°) and 20° (n.v. <15°), respectively [Iughetti et al., 2010] .
The occurrence of occult celiac disease or other chronic gastrointestinal disorder was ruled out by appropriate biochemical analysis; C-reactive protein, thyroid values, renal function, and albumin levels were normal (data not shown). Growth hormone (GH) deficiency was not found (GH peaks >10 ng/ml during 2 provocative GH tests). IGF1 values were in the normal range, but below the mean for age and sex (114.0 ng/ml; -0.62 SD). A normal increase was found after a IGF1 generation test (peak IGF1 value 331.2 ng/ml; Δ-increase + 190%, n.v. >15%) [Pessoa de Queiroz et al., 2007] . No psychiatric causes of impaired growth were found.
Methods

Clinical and Endocrine Evaluation
Standing height was measured with a wall-mounted stadiometer. SD score of height and BMI [weight (kg)/height (m 2 )] was calculated according to WHO standards (www.who.int/ childgrowth/standards/en/). Sitting height/standing height ratio was evaluated according to Spanish normative values [de Arriba Muñoz et al., 2013] . Bone age was determined using X-ray of the nondominant hand and wrist and estimated according to Greulich and Pyle [1959] . Blood samples were drawn in the morning (between 8.00 and 9.00 a.m.), and serum was stored at -20 ° C until analysis. Hormonal assays were performed by commercially available ELISA and chemiluminescence kits.
Cytogenetic Analysis G-and Q-banded chromosomes of cultured peripheral blood lymphocytes and 100 metaphases were analyzed. Briefly, whole blood was cultivated in RPMI-1640 (Celbio, Milan, Italy), supplemented with 2% glutamine, 10% fetal calf serum, and 2% w/v PHA-M (Sigma, St. Louis, Mo., USA) for 72 h at 37 ° C. Chromosome preparations were obtained according to standard techniques.
FISH and Chromosome Painting
FISH studies were performed at standard conditions using a whole Y chromosome-painting probe as well as probes specific for SRY and CEPX/CEPY centromere (Cytocell, Cambridge, 21 UK). Each experiment was carried out according to the manufacturer's instructions. Signals were visualized by a Nikon microscope with an epifluorescent illuminator (Nikon, Tokyo, Japan) and were digitized for documentation with the CytoVision system (Nikon).
Multiple Ligation Probe Assay
MLPA reagents were obtained from MRC-Holland, Amsterdam, The Netherlands (SALSA MLPA kit P018-F1 SHOX). About 100 ng of genomic DNA was used in the test, according to the manufacturer's protocol. Data normalization and data analysis were performed according to the manufacturer's recommendation.
Array CGH
Array CGH was performed according to standard protocols. Briefly, genomic DNA was extracted from peripheral blood lymphocytes of the patient. This DNA and a male reference DNA were labeled differentially with cyanine 3 and 5, using standard procedures. Microarray experiments were performed on DNA microarrays 8x60K (Agilent Technologies, Santa Clara, Calif., USA) that have an ∼ 25-kb average probe spatial resolution. Microarrays were scanned with an Agilent scanner G256BA. Hybridization data analysis was carried out with Agilent Technologies dedicated software. Search for copy number variation regions was performed using the Database of Genomic Variants (http://projects.tcag.ca/cariation/).
Results
A derivative Y chromosome was detected in all examined metaphases of the patient. FISH using a Y chromosome-painting probe confirmed the Y origin of this chromosome. SRY probe showed 2 hybridization signals, and 2 signals were apparent after hybridization with an alfacentromeric Y probe. PCR analysis showed that the azoospermia factor regions were present. The final karyotype was 46,X,idic(Y,Y)(qter → p11.32::p11.32 → qter).ish idic(Y,Y)(qter → p11.32::p11.32 → qter)(SRY++,DYZ3++). The structure of idic(Y) is shown in figure 1 .
MPLA showed an increase of about 50% of the peak areas corresponding to the probes in the PAR1. The probes from 01341-L20651 to 16858-L15742 were duplicated, including the SHOX gene (P018-F1 SALSA MLPA Kit). Sequencing of the coding region of SHOX did not detect any mutations.
Array CGH detected a 248-kb deletion starting from 11,091 to 248,336 (Yp11.32) and a 58-Mb duplication starting from position 248,336 (Yp11.32) to 59,335,913 (Yq12) (Hg19 reference map). After diagnosis of the SHOX duplication, treatment with recombinant GH was started at the dose of 0.33 mg/ kg/week and subdivided in 7 weekly doses. Growth velocity at 6 months (10.6 cm/year) and 12 months (8.6 cm/ year) of follow-up clearly increased in comparison with the value before the beginning of GH administration (4.2 cm/year). A reduction of the growth deficit and a decrease in the slight overweight were recorded during follow-up ( table 1 ) . No abnormal progression of bone age was observed (start of GH therapy: -0.80 SD; 12 months followup: -0.62 SD).
Discussion
In this report, a child with short stature and 3 copies of SHOX is described. He was adopted from a low-income social area, and malnutrition may be involved in both low weight and height at the age 3 years [Rogol and Hayden, 2014] . While BMI progressively normalized after adoption, height did not, suggesting the possibility of a specific cause for his short stature. Extensive investigations ruled out common organic or psychiatric causes of short stature [Rogol and Hayden, 2014; Ghione et al., 2015] , not always explored in the previous short patients with SHOX duplications [D'haene et al., 2010; Iughetti et al., 2010; Benito-Sanz et al., 2011] . Normal GH secretion was found in the case reported by Iughetti et al. [2010] . In the patient of D'haene et al. [2010] , data of clinical and endocrine investigations were not shown. In the series of BenitoSanz et al. [2011] , the children were investigated according to criteria requiring the exclusion of GH deficiency [Cohen et al., 2008] . In the present case, normal GH secretion was also found. The normal increase in IGF1 during an IGF1 generation test, previously unreported in short patients with SHOX duplications, indicates normal GH sensitivity [Pessoa de Queiroz et al., 2007; Bertelloni et al, 2013] .
So, the patient's karyotype constitution [46,X,idic(Y) (p11.3)] may be involved in the origin of short stature. Different mechanisms can be proposed for the formation of this idic(Y), both of them take place during the first meiotic division. The first mechanism involves a terminal deletion in Yp11.3, resulting in the loss of the telomeric Yp and in an unstable chromosome. End fusion of the 2 broken chromatids may occur to stabilize the deleted chromosome, followed by misdivision of the centromere ( fig. 2 ) . The second mechanism involves a misalignment between palindromic sequences in Y PAR1 along sister chromatids, that mediate a NAHR. The acentric fragment is likely lost during cell divisions ( fig. 2 a, b) [Lange et al., 2009] .
The array CGH showed that the breakpoint of the idic(Y) is quite close to the Yp telomere, causing the deletion of 248 kb of the distal portion of PAR1 region. This region does not harbor known genes, whose deletion has been associated with pathological phenotypes. The rearranged idic(Y) chromosome ( fig. 1 ) carries 2 copies of SHOX , leading to a trisomy of the gene. People with triple SHOX due to sex chromosome trisomy usually show tall stature [Aksglaede et al., 2008] . This finding is not always true in individuals with microduplications of PAR1 involving SHOX or its regulatory sequences. In fact, cases with tall, normal and short stature have been reported [Roos et al., 2009; Thomas et al., 2009; D'haene et al., 2010; Iughetti et al., 2010; Benito-Sanz et al., 2011; Brosens et al., 2014] .
The impaired growth pattern of some individuals with isolated SHOX microduplications suggests that expression of the allele harboring the duplication may be reduced or ablated, resulting in functional SHOX haploinsufficiency [Benito-Sanz et al., 2011] . The breakpoint of the microduplications can alter or disrupt its complex transcriptional regulation, in which either specific 5 ′ or 3 ′ regulatory sequences are involved for optimal gene expression [Ellison et al., 1997; Rao et al., 1997; Blaschke et al., 2003] . Regulatory sequences, such as enhancer elements, have been located in the proximity both of the 5 ′ and the 3 ′ gene regions, and they are necessary for temporal-and tissue-specific SHOX expression [Rosin et al., 2013] . The different phenotypes associated with SHOX duplications ( table 2 ) may be related to their size, position and number of transcriptional enhancers within the duplicated interval [Benito-Sanz et al., 2011] . In the present case, the breakpoint is located 44 kb upstream of SHOX , where 5 highly conserved noncoding elements (CNEs) have been identified. All these CNEs are conserved in distantly related species and have enhancer activity in the developing chicken limb [Durand et al., 2010] . Even if all these CNEs are located in the duplicated region of idic(Y), the short stature of this boy may be related to a positional effect of the breakpoint on CNEs, or by disrupted activity of other regulatory sequences not yet characterized.
A literature review indicates that patients with short stature and different extents/positions of SHOX duplications are extremely rare. To our knowledge, only 17 cases including our patient have been described (female to male ratio 1.6: 1.0; table 2 ). Multiple/complex Y rearrangements and mosaic cases were excluded. Few clinical data are reported in some studies and other phenotypic ( table 2 ) . One girl with partial duplication of exons 2-6a was born small for gestational age [Benito-Sanz et al., 2011] , which is a known cause of short stature [Rogol and Hayden, 2014] . Two additional small for gestational age babies with SHOX duplication and complex malformations resembling VACTERL association have been described, but their postnatal growth pattern was not shown [Brosens et al., 2014] . Phenotype may be LWD (47%), mainly in partial duplications, or isolated short stature (53%) in both complete and partial duplications, as in the present case ( table 2 ) . Madelung deformity was present in a minority of patients (44%), all having partial SHOX duplications ( table 2 ) . Patients with LWD phenotype or Madelung deformity without short stature, who have a 5 ′ SHOX duplication are also described [Thomas et al., 2009; BenitoSanz et al., 2011] . The causative role of SHOX duplication in other phenotypic or neurological abnormalities de- scribed in some patients with SHOX duplication [Roos et al., 2009; D'haene et al., 2010; Iughetti et al., 2010; Brosens et al., 2014] requires further investigations, assessing the possible extraskeletal effect of this gene. Indeed, a definite genotype/phenotype correlation is currently not possible, due to the limited number of patients and the difficulties in comparing the extent of duplicated regions. In fact, the use of different in-house FISH clones, as well as different commercial kits for the MLPA analysis, determines some variability in probe specificity and localization. In addition, incomplete penetrance and variable expressivity of SHOX may play a role. The effect of GH therapy in short patients with SHOX duplications was previously unreported. In our case, recombinant GH therapy induced a catch-up growth in the first year of treatment with an increase of growth velocity similar to that observed in SHOX haploinsufficiency [Binder, 2011; Iughetti et al., 2012; Massart et al., 2013] , but efficacy in improving adult height and safety will require long-term follow-up.
In conclusion, SHOX duplications may be a rare cause of short stature. Although expression studies of SHOX are not easy to be performed due to its tissue specificity and temporal regulation, a detailed molecular characterization of the PAR1 region is mandatory when SHOX duplication is found, to better elucidate the correlations between different duplications and their phenotypic consequences. The beneficial effect of GH treatment in this child with SHOX duplication and short stature will be confirmed in other studies.
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